This is usually mild but should be reported immediately if it occurs." Ongoing Monitoring At Each Follow-Up Visit: Ask specifically about tingling, numbness, burning sensations Check sensation in hands and feet Document any new symptoms Assess impact on quality of life Consider Dose Reduction If: Mild dysesthesia present but tolerable Patient achieving good weight loss (can afford slightly less efficacy) Symptoms are bothersome but not severe Consider Discontinuation If: Moderate to severe dysesthesia Progressive symptoms despite dose reduction Functional impairment Patient preference to stop Long-Term Unknowns and Research Needs Critical Questions for Future Studies 1
The main reason behind this is the lack of moisture in the skin of the lips
The quiescent center cells are reminiscent of animal stem cells in their features, and some authors regard them as plant stem cells
G., Sims, J
Liraglutide shares 97% sequence homology with human GLP-1 and can bind to and activate GLP-1R.78 The elimination half-life of liraglutide is 13 h, and only one injection per day is required.62 Lixisenatide Lixisenatide was developed by Sanofi to treat T2DM.64,93 Structurally, lixisenatide is based on the exenatide structure but lacks proline at position 38, and six lysines are linked after serine at position 39.94 The six lysine residues increase the rigidity of the molecules structure, thus allowing its drug properties to be improved.78 These changes stabilize its structure, prevent protein degradation of the molecule in the circulation, and increase the circulation time enough to ensure once-daily injection (compared with exenatide, which is injected two or three times daily)
